Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Status: AVAILABLE
Study type: EXPANDED_ACCESS
Conditions: NRG1 Fusion|Pancreatic Cancer|Non Small Cell Lung Cancer|Solid Tumor, Unspecified, Adult|Prostate Cancer|Head and Neck Cancer|Colorectal Cancer|Breast Cancer|Cholangiocarcinoma|Renal Cell Carcinoma|Unknown Primary Tumors
Interventions: DRUG: MCLA-128
Sponsor: Merus N.V.